|
|
Article: CyDex Pharmaceuticals Announces Successful Completion of Phase II Clinical Trial for Budesonide/Azelastine Combination Solution Nasal Spray.
- Article from:
- Clinical Trials Week
- Article date:
- February 16, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CyDex Pharmaceuticals, Inc. announced that it has successfully completed an early proof-of-concept phase II clinical trial of its Captisol-Enabled[R] budesonide/azelastine nasal spray for seasonal allergic rhinitis (SAR). CyDex has an international PCT patent application pending for this combination nasal spray product (see also CyDex Pharmaceuticals).
A Randomized, Double-Blind, Placebo-Controlled, Three-Way Cross-Over Study was conducted in 108 SAR patients to Compare the Relative Efficacy of Captisol-Enabled[R] Budesonide + Azelastine Nasal Spray (Single Solution) and Rhinocort Aqua (Suspension) + Astelin Nasal Spray (Solution) against Placebo Nasal Spray ...